Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare Fund
Direct Plan where a fund has one, Growth option · Data as on 30-10-2026
Motilal Oswal BSE Healthcare ETF is an ETF fund and Tata India Pharma & Healthcare Fund is a Thematic fund. In the 3 years to 30-10-2026, Motilal Oswal BSE Healthcare ETF returned 22.7% a year and Tata India Pharma & Healthcare Fund (Direct) returned 19.3% a year. Motilal Oswal BSE Healthcare ETF charges 0.36% a year and Tata India Pharma & Healthcare Fund 1.10%. Their portfolios overlap 53.8%: they hold 30 of the same securities.
Motilal Oswal BSE Healthcare ETF
ETF
- 3 year return
- 22.7%
- Expense ratio
- 0.36%
- NAV
- ₹50.91
Tata India Pharma & Healthcare Fund
Thematic
- 3 year return
- 19.3%
- Expense ratio
- 1.10%
- NAV
- ₹37.77
Which is better, Motilal Oswal BSE Healthcare ETF or Tata India Pharma & Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Motilal Oswal BSE Healthcare ETF returned more over 3 years: 22.7% a year against 19.3%.
- Motilal Oswal BSE Healthcare ETF returned more over 1 year: 12.2% against 4.3%.
- Motilal Oswal BSE Healthcare ETF costs less: 0.36% a year against 1.10%.
- Tata India Pharma & Healthcare swung less over 3 years: a standard deviation of 13.2% a year against 14.1%.
- Motilal Oswal BSE Healthcare ETF fell less in its worst fall since 04-08-2022: −16.1% against −16.8%.
- Tata India Pharma & Healthcare is the larger fund: ₹1,511 Cr against ₹44 Cr.
- Their portfolios overlap 53.8%: 30 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Fund house | Motilal Oswal Mutual Fund | Tata Mutual Fund |
| Category | ETF | Thematic |
| AUM | ₹44 Cr (30-09-2026) | ₹1,511 Cr (30-09-2026) |
| NAV | ₹50.91 | ₹37.77 (Direct) |
| Expense ratio (Direct) | Not available | 1.10% |
| Expense ratio (Regular) | Not available | 2.42% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 29-07-2022 | 28-12-2015 |
| Minimum investment | ₹500 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Swapnil Mayekar, Rakesh Shetty | Rajat Srivastava |
| Exit load | Nil | 0.25% of NAV if redeemed /switched out before 30 days from the date of allotment. |
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | +0.22% | −1.05% | +12.72% | +12.16% | +22.69% | -- | -- |
| Tata India Pharma & Healthcare Fund (Direct) | −1.40% | −5.00% | +6.91% | +4.28% | +19.28% | +14.93% | +14.64% |
| Thematic average | −2.09% | −4.52% | +0.86% | −1.22% | +13.76% | +11.62% | +13.76% |
Category average: the average of the 235 Thematic funds, same plan type.
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare: Year-wise Returns
| Year | Motilal Oswal BSE Healthcare ETFMotilal Oswal BSE Healthcare ETF | Tata India Pharma & HealthcareTata India Pharma & Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +14.90% | +6.77% | +15.08% |
| 2025 | −2.93% | −3.47% | −2.72% |
| 2024 | +43.80% | +42.48% | +44.30% |
| 2023 | +37.59% | +38.59% | +37.97% |
| 2022 | -- | −6.64% | −11.50% |
| 2021 | -- | +20.88% | +21.54% |
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 3-year holding period, 305 of them, one for each trading day from 04-08-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Motilal Oswal BSE Healthcare ETF
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
to
Sept 2025Nov 2022
to
Nov 2025Feb 2023
to
Feb 2026Apr 2023
to
Apr 2026Jul 2023
to
Jul 2026Sept 2023
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 0.0 | 0.0 | 0.0 | 0.0 | 1.6 | 72.5 | 25.9 | 24.1% | 24.2% | 19.5% | 28.4% | 0% |
| Tata India Pharma & Healthcare | 0.0 | 0.0 | 0.0 | 0.0 | 9.2 | 71.1 | 19.7 | 23.2% | 23.6% | 16.8% | 26.8% | 12% |
| BSE Healthcare TRI | 0.0 | 0.0 | 0.0 | 0.0 | 0.7 | 63.3 | 36.1 | 24.5% | 24.6% | 19.8% | 28.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 04-08-2022. Past returns do not promise future returns.
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 04-08-2022 to 30-10-2026: 51 instalments, ₹5,10,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETFMotilal Oswal BSE Healthcare ETF | ₹5,10,000 | ₹7,62,270 | ₹2,52,270 | 19.2% |
| Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct) | ₹5,10,000 | ₹7,08,348 | ₹1,98,348 | 15.6% |
Motilal Oswal BSE Healthcare ETFMotilal Oswal BSE Healthcare ETF
Tata India Pharma & HealthcareTata India Pharma & Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +12.16% | +4.28% |
| Standard deviation | 13.58% | 11.99% |
| Sharpe ratio | 0.51 | -0.08 |
| Sortino ratio | 0.75 | -0.11 |
| Maximum drawdown | −10.0% (23-10-2026) | −11.0% (23-10-2026) |
| Beta | 1.00 | 0.82 |
| Alpha | −0.20% | −6.83% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +22.69% | +19.28% |
| Standard deviation | 14.08% | 13.21% |
| Sharpe ratio | 1.18 | 1.00 |
| Sortino ratio | 1.68 | 1.43 |
| Maximum drawdown | −16.1% (28-02-2025) | −16.8% (28-02-2025) |
| Beta | 1.00 | 0.89 |
| Alpha | −0.28% | −1.91% |
From daily NAVs, 30-10-2023 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +20.31% | +13.01% |
| Standard deviation | 13.22% | 15.08% |
| Sharpe ratio | 1.07 | 0.50 |
| Sortino ratio | 1.54 | 0.72 |
| Maximum drawdown | −16.1% (28-02-2025) | −19.8% (21-08-2017) |
| Beta | 1.00 | 0.87 |
| Alpha | −0.29% | +2.53% |
From daily NAVs, 04-08-2022 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Motilal Oswal BSE Healthcare ETF
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | −16.1% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
| Tata India Pharma & Healthcare Fund (Direct) | −16.8% | 02-01-2025 | 28-02-2025 | 11-05-2026 | 14 months | −6.0% |
| BSE Healthcare TRI | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
From daily values since 04-08-2022, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Motilal Oswal BSE Healthcare ETF
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 3-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Motilal Oswal BSE Healthcare ETF
Tata India Pharma & Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Motilal Oswal BSE Healthcare ETF | 99% | 100% | 0.06% |
| Tata India Pharma & Healthcare Fund (Direct) | 95% | 99% | 2.89% |
From month-end values since 04-08-2022. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Motilal Oswal BSE Healthcare ETF, September 2026; Tata India Pharma & Healthcare Fund, September 2026
Holdings in common
- Overlap
- 53.8%
- Held by both
- 30
- Only in Motilal Oswal BSE Healthcare ETF
- 107
- Only in Tata India Pharma & Healthcare
- 11
| Security | % of Motilal Oswal BSE Healthcare ETF | % of Tata India Pharma & Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 12.33% | 7.99% |
| Divi's Laboratories Limited | 7.42% | 5.68% |
| Dr Reddys Laboratories Limited | 4.73% | 4.65% |
| Apollo Hospitals Enterprise Limited | 5.21% | 4.36% |
| Cipla Limited | 4.79% | 4.22% |
| Max Healthcare Institute Limited | 4.32% | 3.71% |
| Torrent Pharmaceuticals Limited | 3.55% | 3.76% |
| Lupin Limited | 3.11% | 3.14% |
| Fortis Healthcare Limited | 2.51% | 1.95% |
| Alkem Laboratories Limited | 1.89% | 2.36% |
| Sai Life Sciences Limited | 1.30% | 2.60% |
| Aster DM Quality Care Limited | 1.18% | 1.67% |
| Acutaas Chemicals Limited | 1.06% | 1.95% |
| Ajanta Pharma Limited | 1.02% | 1.63% |
| Dr. Lal Path Labs Limited | 0.96% | 1.76% |
| IPCA Laboratories Limited | 1.69% | 0.91% |
| Abbott India Limited | 0.87% | 5.94% |
| Mankind Pharma Limited | 1.75% | 0.77% |
| GlaxoSmithKline Pharmaceuticals Limited | 0.71% | 0.76% |
| Biocon Limited | 1.63% | 0.69% |
| Anthem Biosciences Limited | 0.58% | 2.57% |
| Natco Pharma Limited | 0.46% | 1.51% |
| Syngene International Limited | 0.43% | 2.85% |
| Rainbow Childrens Medicare Limited | 0.42% | 4.30% |
| Pfizer Limited | 0.37% | 2.50% |
| Procter & Gamble Health Limited | 0.28% | 2.75% |
| Dr Agarwals Health Care Limited | 0.23% | 0.68% |
| Healthcare Global Enterprises Limited | 0.22% | 5.92% |
| Sanofi Consumer Healthcare India Limited | 0.16% | 0.57% |
| FDC Limited | 0.10% | 2.24% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 53.8% means 53.8% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Motilal Oswal BSE Healthcare ETF
| Security | % of fund |
|---|---|
| Laurus Labs Limited | 4.84% |
| Aurobindo Pharma Limited | 2.89% |
| Glenmark Pharmaceuticals Limited | 2.17% |
| Zydus Lifesciences Limited | 1.82% |
| Gland Pharma Limited | 1.44% |
Largest holdings only in Tata India Pharma & Healthcare Fund
| Security | % of fund |
|---|---|
| BAYER CROPSCIENCE LTD | 2.96% |
| PI INDUSTRIES LTD | 2.59% |
| SUMITOMO CHEMICAL INDIA LTD | 1.38% |
| GILLETTE INDIA LTD | 1.23% |
| NAVIN FLUORINE INTERNATIONAL LTD | 1.18% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare |
|---|---|---|
| Equity | 99.9% | 99.7% |
| Debt | 0.0% | 0.0% |
| Cash and others | 0.1% | 0.3% |
Market cap of stocks
| Market cap | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare |
|---|---|---|
| Large Cap | 33.3% | 26.0% |
| Mid Cap | 38.5% | 33.9% |
| Small Cap | 27.8% | 37.0% |
| Not on AMFI's list | 0.3% | 2.9% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 78.0% | 60.6% |
| Healthcare Services | 21.4% | 27.8% |
| Fertilizers & Agrochemicals | 0.0% | 6.9% |
| Chemicals & Petrochemicals | 0.0% | 2.6% |
| Personal Products | 0.0% | 1.2% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Motilal Oswal BSE Healthcare ETF | Tata India Pharma & Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | Not available | 1.10% |
| Base expense ratio (Direct) | 0.00% | 0.64% |
| Total expense ratio (Regular) | Not available | 2.42% |
| Base expense ratio (Regular) | 0.21% | 1.82% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Tata India Pharma & Healthcare with
- Tata India Pharma & Healthcare vs Nippon India Taiwan Equity
- Tata India Pharma & Healthcare vs HDFC Defence
- Tata India Pharma & Healthcare vs HDFC Pharma and Healthcare
- Tata India Pharma & Healthcare vs SBI Healthcare Opportunities
- Tata India Pharma & Healthcare vs Aditya Birla Sun Life International Equity
Motilal Oswal BSE Healthcare ETF vs Tata India Pharma & Healthcare Fund: Frequently Asked Questions
What is the difference between Motilal Oswal BSE Healthcare ETF and Tata India Pharma & Healthcare Fund?
Motilal Oswal BSE Healthcare ETF is an ETF fund, Tata India Pharma & Healthcare Fund is a Thematic fund, run by Motilal Oswal Mutual Fund and Tata Mutual Fund. Their portfolios overlap 53.8%. Motilal Oswal BSE Healthcare ETF charges 0.36% a year and Tata India Pharma & Healthcare Fund 1.10%.
Which has given higher returns, Motilal Oswal BSE Healthcare ETF or Tata India Pharma & Healthcare Fund?
Over 1 year: Motilal Oswal BSE Healthcare ETF +12.16%, Tata India Pharma & Healthcare Fund +4.28%. Over 3 years: Motilal Oswal BSE Healthcare ETF +22.69% a year, Tata India Pharma & Healthcare Fund +19.28% a year. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Motilal Oswal BSE Healthcare ETF or Tata India Pharma & Healthcare Fund?
Motilal Oswal BSE Healthcare ETF charges less: 0.36% a year against 1.10%. These are the total expense ratios reported to AMFI.
How much do Motilal Oswal BSE Healthcare ETF and Tata India Pharma & Healthcare Fund overlap?
53.8%. They hold 30 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, DRREDDY. From each fund's latest monthly portfolio.
Which is riskier, Motilal Oswal BSE Healthcare ETF or Tata India Pharma & Healthcare Fund?
On SEBI's riskometer, Motilal Oswal BSE Healthcare ETF is rated Very High and Tata India Pharma & Healthcare Fund Very High. Over 3 years, the standard deviation of daily returns was 14.08% and 13.21% a year.
Which is better for SIP, Motilal Oswal BSE Healthcare ETF or Tata India Pharma & Healthcare Fund?
Over the last 3 years, a monthly SIP of ₹10,000 from 03-10-2023 to 30-10-2026 grew to ₹4,63,433 in Motilal Oswal BSE Healthcare ETF (XIRR 14.8% a year) and ₹4,31,361 in Tata India Pharma & Healthcare Fund (XIRR 10.0% a year). Both received 37 instalments. Past returns do not promise future returns.
Can I invest in both Motilal Oswal BSE Healthcare ETF and Tata India Pharma & Healthcare Fund?
Yes. 53.8% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Motilal Oswal BSE Healthcare ETF and Tata India Pharma & Healthcare Fund?
Motilal Oswal BSE Healthcare ETF: Swapnil Mayekar, Rakesh Shetty. Tata India Pharma & Healthcare Fund: Rajat Srivastava.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.